89Bio debuts IPO
San Francisco and Israel-based 89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders, has raised about $84.9 million for its IPO after pricing its over 5.3 million shares at $16 per share. The stock began trading November 11, 2019 on the NASDAQ under the ticker symbol "ETNB." BofA Securities, SVB Leerink and RBC Capital Markets are the lead underwriters. 89Bio's pre-IPO backers include OrbiMed Israel, OrbiMed US, Longitude Capital, RA Capital Management and Pontifax.
11 November 2019•3 mins read
